SpyGlass Pharma Inc. (NASDAQ: SGP) appointed Mike Pinder as vice president of marketing, the company announced. Pinder brings more than 20 years of commercial launch experience in ophthalmology.

At SpyGlass Pharma, Pinder will build and lead the marketing function as the company progresses its Bimatoprost Drug Pad-IOL System through Phase 3 clinical trials toward potential commercialization upon FDA approval.

Pinder was most recently head of IZERVAY marketing at Astellas Pharma. He previously led patient marketing in the Novartis ophthalmology retina franchise and held hospital marketing positions at Johnson & Johnson. He holds a Bachelor of Arts degree in communications from the University of Massachusetts Amherst.

"Mike's deep experience in building successful ophthalmology brands across buy-and-bill specialty pharma and medical device products will augment our plans for a successful BIM-IOL launch," said Patrick Mooney, chief executive officer of SpyGlass Pharma.

SpyGlass Pharma is currently enrolling participants in two Phase 3 trials for its BIM-IOL System. The company focuses on developing sustained drug delivery solutions for chronic eye conditions.

The information is based on a company press release.